Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sight Sciences Inc (SGHT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SGHT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -8.11% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 130.90M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 294509 | Beta 2.51 | 52 Weeks Range 2.17 - 8.45 | Updated Date 04/1/2025 |
52 Weeks Range 2.17 - 8.45 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.176 | Actual -0.23 |
Profitability
Profit Margin -64.49% | Operating Margin (TTM) -62.54% |
Management Effectiveness
Return on Assets (TTM) -20.41% | Return on Equity (TTM) -49.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 43203465 | Price to Sales(TTM) 1.64 |
Enterprise Value 43203465 | Price to Sales(TTM) 1.64 | ||
Enterprise Value to Revenue 0.54 | Enterprise Value to EBITDA -4.25 | Shares Outstanding 51332700 | Shares Floating 31494148 |
Shares Outstanding 51332700 | Shares Floating 31494148 | ||
Percent Insiders 20.6 | Percent Institutions 54.74 |
Analyst Ratings
Rating 3.29 | Target Price 5.02 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sight Sciences Inc
Company Overview
History and Background
Sight Sciences Inc. was founded in 2011 and is a growth-stage medical device company transforming the two largest and fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. They have developed proprietary technology incorporating both micro-surgical and drug delivery approaches, and integrated into a portfolio of FDA-cleared devices that target the underlying causes of the world's most prevalent eye diseases.
Core Business Areas
- Glaucoma: Sight Sciences provides surgical glaucoma solutions focused on lowering intraocular pressure (IOP) and reducing the need for glaucoma medication. Their flagship product is the OMNI Surgical System.
- Dry Eye Disease: Sight Sciences offers solutions for dry eye disease, focusing on addressing underlying causes by clearing obstructions in the meibomian glands. TearCare System is their main offering in this segment.
Leadership and Structure
Paul Badawi is the CEO and Co-Founder. The company has a typical organizational structure with departments for R&D, sales and marketing, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- OMNI Surgical System: A minimally invasive glaucoma surgery (MIGS) system that allows surgeons to perform multiple procedures in a single intervention, addressing outflow resistance in Schlemm's canal and the trabecular meshwork. Estimations place Sight Sciences OMNI market share in the low single digits in the MIGS market. Competitors include Glaukos (GKOS), Ivantis (acquired by Alcon), and Allergan (now AbbVie).
- TearCare System: A wearable device for the treatment of dry eye disease by applying targeted heat to the meibomian glands. Sight Sciences is a smaller player in the dry eye market. Competitors include Johnson & Johnson Vision (JJNJ), Alcon (ALC), and Bausch + Lomb (BLCO).
Market Dynamics
Industry Overview
The ophthalmology market is experiencing growth driven by an aging population, increasing prevalence of eye diseases, and technological advancements in treatments. The glaucoma and dry eye disease segments are particularly large and growing.
Positioning
Sight Sciences is positioned as a growth-stage company with innovative technology in the MIGS and dry eye spaces. They aim to disrupt the market with comprehensive solutions that address the underlying causes of these diseases.
Total Addressable Market (TAM)
The TAM for glaucoma and dry eye treatments is estimated to be billions of dollars globally. Sight Sciences is focused on capturing a larger share of this market through product innovation and market penetration.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- FDA-cleared products
- Targeting large and growing markets
- Strong intellectual property portfolio
Weaknesses
- Limited market share compared to established players
- Reliance on key products
- Requires sales growth to show profitability
- Cash burn due to expansion
Opportunities
- Expand product portfolio
- Increase market penetration
- Develop partnerships
- Geographic expansion
Threats
- Competition from established players
- Technological advancements by competitors
- Reimbursement challenges
- Regulatory changes
Competitors and Market Share
Key Competitors
- GKOS
- ALC
- BLCO
Competitive Landscape
Sight Sciences competes with larger, more established companies in the ophthalmology market. Its innovative technology and focus on addressing underlying causes of eye diseases give it a competitive edge, but its smaller size and limited resources present challenges.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Sight Sciences has demonstrated strong revenue growth in recent years, driven by increased adoption of its OMNI and TearCare systems.
Future Projections: Analyst estimates project continued revenue growth for Sight Sciences, driven by expanding market share and new product launches. Profitability is expected in the coming years.
Recent Initiatives: Recent strategic initiatives include expanding the sales force, launching new products, and pursuing strategic partnerships.
Summary
Sight Sciences is a medical device company showing growth and innovation in the ophthalmology space, particularly with its surgical glaucoma and dry eye solutions. While it competes against larger, established players, its unique technology offers a competitive advantage. The company's growth trajectory is promising but it needs to work toward profitability and better market share. They should look out for reimbursement challenges, and competition from larger companies.
Similar Companies
ALC
Alcon AG
ALC
Alcon AG
BLCO
Bausch + Lomb Corp
BLCO
Bausch + Lomb Corp
GKOS
Glaukos Corp
GKOS
Glaukos Corp
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Market research reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sight Sciences Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2021-07-15 | Co-Founder, President, CEO & Director Mr. Paul Badawi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 216 | Website https://www.sightsciences.com |
Full time employees 216 | Website https://www.sightsciences.com | ||
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform procedures for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure; and SION surgical instrument, a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also offers TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.